The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant olaparib plus pembrolizumab in HRD-positive stage III–IV high-grade serous or endometrioid ovarian cancer achieved a 70% overall response rate (95% CI 45.7–88.1).
- Why it matters: Preclinical synergy between PARP inhibition and immune checkpoint blockade is suggested, but clinical evidence in HRD-positive advanced ovarian cancer has been limited.
- What they did: In a pilot neoadjuvant study, patients received olaparib alone (300 mg twice daily for 6 weeks; n=10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; n=20), then underwent surgery and platinum-based chemotherapy; ORR was the primary endpoint.
- The result: The ORR was 50% (95% CI 18.7–81.3) with olaparib alone (P=0.2839), and immune analyses showed increased CD8+ T-cell infiltration and immune-related transcriptional changes with the combination, without unexpected toxicities.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.